PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation. |
| |
Authors: | Lisa Patel Steven J Charlton Ian C Marshall Gary B T Moore Phil Coxon Kitty Moores John C Clapham Suzanna J Newman Stephen A Smith Colin H Macphee |
| |
Institution: | Department of Vascular Biology, Department of Analytical Sciences, GlaxoSmithKline, New Frontiers Science Park North, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom. Lisa_Patel-1@gks.com |
| |
Abstract: | In the present report we clarify the role of PPARgamma in differentiation and function of human-derived monocyte/macrophages in vitro. Rosiglitazone, a selective PPARgamma activator, had no effect on the kinetics of appearance of monocyte/macrophage differentiation markers or on cell size or granularity. Depletion of PPARgamma by more than 90% using antisense oligonucleotides did not influence accumulation of oxidized LDL or prevent the upregulation of CD36 that normally accompanies oxLDL treatment. In contrast, PPARgamma depletion reduced the expression of ABCA1 and LXRalpha mRNAs. Metalloproteinase-9 expression, a marker of atherosclerotic plaque vulnerability, was suppressed by rosiglitazone. We conclude that activation of PPARgamma does not affect monocyte/macrophage differentiation. In addition, PPARgamma is not absolutely required for oxLDL-driven lipid accumulation, but is required for full expression of ABCA1 and LXRalpha. Our data support a role for rosiglitazone as a potential directly acting antiatherosclerotic agent. |
| |
Keywords: | PPARγ rosiglitazone monocyte macrophage ABCA1 LXRα |
本文献已被 ScienceDirect 等数据库收录! |
|